[Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
D002784:Cholesterol / Q000097:blood; D016527:Drug Costs; D016568:Drugs, Generic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D016568:Drugs, Generic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol; D019821:Simvastatin
Effektivnost', bezopasnost' i farmakoékonomicheskie aspekty lecheniia dislipidemiĭ original'nym i genericheskim statinami.